Until the identification of leptin, the first adipokine discovered in 1994, adipose tissue was
considered only as an energy storage tissue. However, it is now clear that adipose tissue is …

This review describes the recent developments in the pathobiology of endothelial
dysfunction (ED) in the context of cirrhosis with portal hypertension and defines novel …

Advanced liver fibrosis in nonalcoholic steatohepatitis (NASH) is often accompanied by a
reduction in hepatic fat to the point of complete fat loss (burnt‐out NASH), but the …

Liver fibrosis can progress to cirrhosis, which is considered a serious disease. The Child-
Pugh score and the model of end-stage liver disease score have been established to assess …

The adipose tissue has recently emerged as an important endocrine organ releasing
numerous mediators including adipocytokines, classical cytokines and others. Adiponectin …

Adiponectin is the most abundant adipokine synthesized by adipose tissue and has been
shown to be a key component in the relationship between adiposity, insulin resistance and …

Silybin, a natural antioxidant, has been traditionally used against a variety of liver ailments.
To investigate its effect and the underlying mechanisms of action on non-alcoholic fatty liver …

Hepatic stellate cells (HSC) are central players in liver fibrosis that when activated,
proliferate, migrate to sites of liver injury, and secrete extracellular matrix. Obesity, a known …

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic
syndrome and can progress to cirrhosis, liver failure, and hepatocellular carcinoma. In the …

The review describes the role of adiponectin in liver diseases in the presence and absence
of surgery reported in the literature in the last ten years. The most updated therapeutic …